drugset / Trial / NCT04654611
Tafluprost Preservative Free Switch Study
NaSingle-groupOpen-labelTreatment
Summary
This study is conducted to document the effect of switching from preserved prostaglandin analogues monotherapy to preservative free tafluprost 0.0015%. The endpoints analyzed are side effect improvement in these patients.
Timeline
- Start
- 2019-02-01
- Primary completion
- 2020-02-01
- Completion
- 2020-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tafluprost | Other / unclassified | 0.0015 % | Topical |